NeoVec Biotherapeutics

NeoVec Biotherapeutics is a biotechnology company spun out from the University of Oxford, focused on developing next-generation viral vectors for gene therapy. The company's proprietary platform utilizes "enveloped" viral vectors that aim to combine the high delivery efficiency of viral systems with the safety and low immunogenicity of non-viral delivery methods. NeoVec's technology is designed to overcome the limitations of current AAV and lentiviral vectors, such as limited payload capacity and pre-existing immunity. The company is currently in the pre-clinical stage, targeting applications in oncology and rare diseases.